Skip to main content
Premium Trial:

Request an Annual Quote

Fluxion, Stanford Team on CTC Test Development

NEW YORK (GenomeWeb) – Fluxion Biosciences said today that it will collaborate with the Stanford University School of Medicine on developing molecular diagnostic tests to identify circulating tumor cells.

The South San Francisco, Calif.-based firm said that Stanford researchers are using its IsoFlux System to "isolate, recover, and analyze rare circulating cancer cells at the molecular level." It expects the collaboration will yield tests that enable the delivery of more effective therapies for cancer patients. The initial focus of the collaboration is prostate and kidney cancer.

Fluxion's IsoFlux can be used in performing a liquid biopsy to collect the CTCs. The cells can then be analyzed by next-generation sequencing for cancer mutational profiling.

"Cancer is a dynamic disease, and the ability to track changes in each patient via a blood sample can allow actionable changes to be detected much earlier," Fluxion Chief Technology Officer Cristian Ionescu-Zanetti said in a statement. "One aim of the collaboration is to identify markers that can help stratify patients requiring more aggressive treatment from those that don't. This is currently a major challenge in the treatment of prostate cancer."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.